Platinum Industries Subsidiary Inks Exclusive India Deal with Korea’s CAREGEN

Key numbers

Market Cap	₹1,130.96 CrSmall Cap
Revenue TTM	₹443.99 CrOperating
Net Profit TTM	₹50.38 CrProfitability
PE TTM	22.45xSector 36.98x
Order from	CAREGEN Co., Ltd., Korea

Key highlights

• Rivadu Lifesciences signed an exclusive agreement with CAREGEN Co., Ltd. on September 28, 2026
• The deal grants exclusive rights to market Korglutide health functional food products in India
• Agreement includes significant provisions for establishing future manufacturing facilities in India
• CAREGEN is a KOSDAQ-listed leader in peptide research with over 800 global patents
• Move represents a strategic diversification for Platinum Industries into the life sciences sector

What Is the Partnership?

Rivadu Lifesciences Private Limited, a subsidiary of Platinum Industries Limited, has entered into a definitive exclusive Sale/Purchase Agreement with South Korea-based CAREGEN Co., Ltd. The agreement, executed on September 28, 2026, grants Rivadu exclusive rights to the Indian territory for CAREGEN’s health functional food finished products marketed under the brand name Korglutide. This partnership represents a formal entry into the specialized nutraceutical market, focusing on finished products that utilize synthetic peptide technology.

The contract also includes significant provisions regarding prospects for establishing domestic manufacturing facilities in India for these products in the future, aligning with national supply chain initiatives.

Partner Profile

• CAREGEN Co., Ltd. is a publicly listed biotechnology firm on the KOSDAQ in South Korea and a global leader in peptide research
• The company has developed over 1,800 proprietary peptides and holds more than 800 global patents across pharmaceuticals and nutraceuticals
• Its Korglutide brand targets metabolic health and weight management by mimicking the GLP-1 hormone, offering a nutraceutical alternative to injectables
• CAREGEN operates a fully integrated value chain and exports biotechnological solutions to over 130 countries worldwide
• The company specializes in biomimetic peptides that support healthy aging and preventive wellness applications

Strategic Expansion and Market Context

Platinum Industries Limited has historically operated as a specialty chemicals manufacturer, providing stabilizers and lubricants for the PVC and CPVC industries. The incorporation of Rivadu Lifesciences in early 2026 and this subsequent partnership with CAREGEN mark a strategic diversification into the high-value life sciences and wellness sectors. By targeting the high-growth Indian nutraceutical market, which is projected to exceed 42 billion dollars by the end of 2026, the company is shifting its industrial focus toward high-margin functional foods.

This move leverages the rising consumer demand for science-backed preventive healthcare solutions and broadens the parent company's portfolio beyond traditional chemical additives.

Financial Position

• Platinum Industries reported a trailing twelve-month operating revenue of 443.99 crore rupees
• The company maintains strong internal control with a latest promoter holding of 70.03 percent
• Platinum Industries trades at a TTM P/E of 22.45x, compared to an industry average P/E of 46.34x
• Annual revenue growth was recorded at 13.78 percent, supported by international exports which contribute over 55 percent of consolidated revenue

Platinum Industries · financial snapshot

Share price	₹205.91
Market capitalisation	₹1,130.96 Cr
Revenue (annual)	₹450.44
Net profit (annual)	₹51.96
P/E (TTM)	22.45×Sector 36.98×
Promoter holding	70.03%0.00% QoQ
FII holding	0.35%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.